+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Single-target MET TKIs Market - Global Forecast 2026-2032- Product Image
Single-target MET TKIs Market - Global Forecast 2026-2032- Product Image
Sale

Single-target MET TKIs Market - Global Forecast 2026-2032

  • Report

  • 188 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6129295
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Single-target MET TKIs Market is projected to reach USD 1.45 Billion in 2026. It is expected to continue growing at a CAGR of 12.49%, reaching USD 2.94 Billion by 2032.

Single-Target MET TKIs: Executive Summary

Single-target MET tyrosine kinase inhibitors (TKIs) are designed to selectively inhibit signaling mediated by the MET receptor, a pathway implicated in tumor growth, survival, invasion, and treatment resistance. Their clinical relevance is closely tied to identifying patients whose tumors contain actionable MET alterations, including exon 14 skipping, amplification, or other dysregulation. Development and adoption therefore depend on biomarker testing, regulatory evidence, treatment sequencing, and specialist familiarity with MET-driven disease.

Precision Oncology Is Reshaping the MET TKI Landscape

The landscape is shifting from broad pathway inhibition toward biomarker-defined treatment. Companion-diagnostic capabilities, more refined molecular classification, and improved understanding of resistance mechanisms are influencing clinical-trial design and prescribing decisions. Selectivity remains important because it can support focused pathway inhibition, while safety management, central nervous system activity, durability of response, and compatibility with prior or subsequent therapies remain central differentiators in clinical practice.

Evidence generation is also becoming more integrated across testing, treatment, and monitoring. Real-world data, prospective registries, and decentralized diagnostic access can help clarify outcomes in less common MET-altered populations, where conventional trial recruitment may be challenging.

Artificial Intelligence Strengthens MET Biomarker and Treatment Workflows

Artificial intelligence can improve the cumulative impact of single-target MET TKIs by supporting interpretation of next-generation sequencing, pathology, radiology, and longitudinal clinical records. Machine-learning systems may help identify subtle exon 14 alterations, distinguish potentially actionable amplification from incidental findings, and prioritize patients for molecular review. These applications require validation against clinically curated datasets and careful management of false positives, data quality, and interpretability.

AI may also assist with response assessment, toxicity surveillance, resistance analysis, and trial matching. Its value is greatest when embedded in multidisciplinary workflows rather than treated as a substitute for molecular tumor boards or clinical judgment. Governance, patient consent, cybersecurity, and equitable access should accompany implementation.

Regional Insights: Testing Infrastructure Drives Access and Adoption

North America generally benefits from mature precision-oncology infrastructure, broad specialist networks, and established molecular-testing pathways, although reimbursement variation and uneven access can affect patient identification. Europe combines strong academic oncology capabilities with differing national health-technology assessments, diagnostic policies, and reimbursement procedures. Asia-Pacific includes advanced treatment and testing ecosystems alongside major disparities in laboratory capacity, regulatory processes, and specialist availability.

Latin America faces variation in access to comprehensive genomic testing, specialist care, and medicines across health systems. The Middle East is developing precision-oncology capacity through tertiary centers, international collaborations, and centralized services, while affordability and referral pathways remain important. Africa has growing oncology and molecular-diagnostics initiatives but continues to face constraints involving infrastructure, workforce, specimen logistics, and treatment access. Across all regions, reliable biomarker testing and coordinated referral systems are foundational.

Group Insights: Policy Alignment and Diagnostic Coordination Matter

ASEAN markets show the importance of interoperable diagnostic pathways and regional collaboration because testing capacity, reimbursement, and regulatory maturity differ substantially among member states. BRICS countries combine significant research and healthcare capabilities with pronounced variation in access, laboratory standards, and treatment affordability. The European Union benefits from shared scientific and regulatory structures, but national reimbursement and health-technology-assessment decisions still shape practical availability.

G7 countries generally possess advanced oncology infrastructure and clinical-research networks, while continuing to address diagnostic equity, evidence requirements, and healthcare-cost pressures. GCC states are strengthening centralized and specialized cancer services, creating opportunities for coordinated testing and referral models. NATO members span diverse healthcare systems, so defense-related collaboration does not eliminate differences in civilian oncology access, reimbursement, or molecular testing.

Country Insights: National Systems Shape MET TKI Pathways

Australia has strong tertiary oncology services and molecular research capabilities, with access influenced by national reimbursement and geographic concentration of specialist care. Brazil and Mexico face meaningful regional variation in genomic testing, oncology referral capacity, and public-versus-private access. Canada and the United States have established precision-oncology ecosystems, although provincial or payer-specific coverage, testing turnaround, and affordability can differ. China is expanding molecular diagnostics and oncology infrastructure across major centers, while access remains uneven between urban and less-served areas.

France, Germany, Italy, Spain, and the United Kingdom combine substantial clinical expertise with national or regional evidence and reimbursement processes that affect adoption. India has rapidly developing oncology and diagnostic capabilities but considerable variation in affordability, laboratory access, and specialist availability. Japan and South Korea maintain advanced cancer-care systems and strong diagnostic expertise, with local regulatory and reimbursement requirements shaping use. Russia’s access landscape is influenced by healthcare-system capacity, procurement conditions, and availability of specialized molecular testing.

Actions for Leaders: Build the Full Biomarker-to-Treatment Pathway

Industry leaders should prioritize validated, accessible testing for clinically relevant MET alterations and establish clear handoffs among pathology laboratories, oncologists, radiologists, and molecular tumor boards. Evidence programs should address response durability, central nervous system outcomes, resistance, sequencing, and patient-reported quality of life, while reflecting routine-care populations. Partnerships with diagnostic providers and healthcare systems can improve turnaround times and reduce avoidable treatment delays.

Operationally, leaders should invest in education on patient selection, adverse-event recognition, drug interactions, and treatment monitoring. Market access planning should account for country-specific reimbursement and health-technology-assessment requirements without relying on unsupported assumptions about demand. AI initiatives should begin with defined clinical use cases, prospective validation, transparent governance, and measurable effects on diagnostic accuracy or care coordination.

Research Methodology: Evidence-Based Synthesis of the MET TKI Ecosystem

This executive summary uses a structured synthesis of established clinical, scientific, regulatory, and healthcare-delivery concepts related to single-target MET TKIs. The assessment considers the biology of MET signaling, actionable biomarker categories, diagnostic workflows, treatment-development priorities, regional health-system characteristics, and organizational groupings specified for review.

Interpretations are framed qualitatively and avoid unsupported estimates, market sizing, market shares, forecasts, or company-specific claims. Regional, group, and country observations reflect differences in oncology infrastructure, molecular-testing capacity, reimbursement, regulatory practice, and specialist access. In practice, decisions should be confirmed against current clinical guidelines, local regulatory documents, reimbursement policies, and peer-reviewed evidence.

Conclusion: Selective MET Inhibition Depends on Integrated Precision Care

Single-target MET TKIs occupy an important role in biomarker-driven oncology, but their value depends on more than pharmacologic selectivity. Accurate alteration detection, timely specialist interpretation, appropriate patient selection, resistance monitoring, safety management, and equitable access must operate as one coordinated pathway.

The strongest opportunities lie in connecting molecular diagnostics with clinical decision-making across diverse health systems. Leaders that combine rigorous evidence generation, practical testing access, responsible AI, and regionally adapted implementation will be better positioned to translate MET biology into consistent patient benefit.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Single-target MET TKIs Market, by Product
7.1. Introduction
7.2. Capmatinib
7.3. Savolitinib
7.4. Tepotinib
8. Single-target MET TKIs Market, by Indication
8.1. Introduction
8.2. Gastric Cancer
8.3. Non Small Cell Lung Cancer
8.3.1. Amplification
8.3.2. Exon 14 Skipping
9. Single-target MET TKIs Market, by Mechanism
9.1. Introduction
9.2. Multi Kinase
9.3. Selective Targeted
10. Single-target MET TKIs Market, by Route Of Administration
10.1. Introduction
10.2. Intravenous
10.3. Oral
11. Single-target MET TKIs Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Retail Pharmacy
12. Single-target MET TKIs Market, by End User
12.1. Introduction
12.2. Hospitals
12.3. Specialty Clinics
13. Single-target MET TKIs Market, by Region
13.1. Introduction
13.2. Asia-Pacific
13.3. North America
13.4. Latin America
13.5. Europe
13.6. Middle East
13.7. Africa
14. Single-target MET TKIs Market, by Group
14.1. Introduction
14.2. ASEAN
14.3. GCC
14.4. European Union
14.5. BRICS
14.6. G7
14.7. NATO
15. Single-target MET TKIs Market, by Country
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. United Kingdom
15.7. Germany
15.8. France
15.9. Russia
15.10. Italy
15.11. Spain
15.12. China
15.13. India
15.14. Japan
15.15. Australia
15.16. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. AbbVie Inc.
17.2. Apollomics Inc.
17.3. AstraZeneca PLC
17.4. Avistone Pharmaceuticals Biotechnology Company
17.5. BeiGene, Ltd.
17.6. Blueprint Medicines Corporation
17.7. Daiichi Sankyo Company, Limited
17.8. Eli Lilly and Company
17.9. Exelixis, Inc.
17.10. Haihe Biopharma Co., Ltd.
17.11. Hanmi Pharmaceutical Co., Ltd.
17.12. HUTCHMED (China) Limited
17.13. Incyte Corporation
17.14. Merck KGaA
17.15. Mirati Therapeutics, Inc.
17.16. Novartis AG
17.17. Nuvation Bio Inc.
17.18. Pfizer Inc.
17.19. Regeneron Pharmaceuticals, Inc.
17.20. Repare Therapeutics, Inc.
17.21. Samsung Bioepis Co., Ltd.
17.22. Sanofi S.A.
17.23. Symphogen A/S
17.24. Takeda Pharmaceutical Company Limited
17.25. Turning Point Therapeutics, Inc.
18. Key Experts
LIST OF FIGURES
FIGURE 1. Global Single-target MET TKIs Market, Years Considered for the Study
FIGURE 2. Global Single-target MET TKIs Market, Research Design
FIGURE 3. Global Single-target MET TKIs Market, Research Framework
FIGURE 4. Global Single-target MET TKIs Market, Data Triangulation
FIGURE 5. Global Single-target MET TKIs Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Single-target MET TKIs Market Size, by Product, 2025 vs 2032 (%)
FIGURE 7. Global Single-target MET TKIs Market Size, by Product, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Single-target MET TKIs Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 9. Global Single-target MET TKIs Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Single-target MET TKIs Market Size, by Mechanism, 2025 vs 2032 (%)
FIGURE 11. Global Single-target MET TKIs Market Size, by Mechanism, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Single-target MET TKIs Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 13. Global Single-target MET TKIs Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Single-target MET TKIs Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 15. Global Single-target MET TKIs Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Single-target MET TKIs Market Size, by End User, 2025 vs 2032 (%)
FIGURE 17. Global Single-target MET TKIs Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Single-target MET TKIs Market Size, by Region, 2025 vs 2032 (%)
FIGURE 19. Global Single-target MET TKIs Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Single-target MET TKIs Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Single-target MET TKIs Market Size, by Country, 2025 vs 2032 (%)
FIGURE 22. Global Single-target MET TKIs Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global Single-target MET TKIs Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Single-target MET TKIs Market Segmentation & Coverage
TABLE 2. Global Single-target MET TKIs Market Size, 2017-2032 (USD Million)
TABLE 3. Global Single-target MET TKIs Market Size, by Product, 2017-2032 (USD Million)
TABLE 4. Global Capmatinib Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Capmatinib Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Capmatinib Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Savolitinib Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Savolitinib Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Savolitinib Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Tepotinib Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Tepotinib Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Tepotinib Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Single-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 14. Global Gastric Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global Gastric Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global Gastric Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Non Small Cell Lung Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Non Small Cell Lung Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Non Small Cell Lung Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Amplification Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Amplification Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Amplification Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Exon 14 Skipping Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Exon 14 Skipping Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Exon 14 Skipping Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Single-target MET TKIs Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 27. Global Multi Kinase Market Size, by Region, 2017-2032 (USD Million)
TABLE 28. Global Multi Kinase Market Size, by Group, 2017-2032 (USD Million)
TABLE 29. Global Multi Kinase Market Size, by Country, 2017-2032 (USD Million)
TABLE 30. Global Selective Targeted Market Size, by Region, 2017-2032 (USD Million)
TABLE 31. Global Selective Targeted Market Size, by Group, 2017-2032 (USD Million)
TABLE 32. Global Selective Targeted Market Size, by Country, 2017-2032 (USD Million)
TABLE 33. Global Single-target MET TKIs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 34. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Single-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 41. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Single-target MET TKIs Market Size, by End User, 2017-2032 (USD Million)
TABLE 48. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Single-target MET TKIs Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Asia-Pacific Single-target MET TKIs Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Asia-Pacific Single-target MET TKIs Market Size, by Product, 2017-2032 (USD Million)
TABLE 57. Asia-Pacific Single-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 58. Asia-Pacific Single-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 59. Asia-Pacific Single-target MET TKIs Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 60. Asia-Pacific Single-target MET TKIs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 61. Asia-Pacific Single-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 62. Asia-Pacific Single-target MET TKIs Market Size, by End User, 2017-2032 (USD Million)
TABLE 63. North America Single-target MET TKIs Market Size, by Region, 2017-2032 (USD Million)
TABLE 64. North America Single-target MET TKIs Market Size, by Product, 2017-2032 (USD Million)
TABLE 65. North America Single-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 66. North America Single-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 67. North America Single-target MET TKIs Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 68. North America Single-target MET TKIs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 69. North America Single-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 70. North America Single-target MET TKIs Market Size, by End User, 2017-2032 (USD Million)
TABLE 71. Latin America Single-target MET TKIs Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Latin America Single-target MET TKIs Market Size, by Product, 2017-2032 (USD Million)
TABLE 73. Latin America Single-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 74. Latin America Single-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 75. Latin America Single-target MET TKIs Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 76. Latin America Single-target MET TKIs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 77. Latin America Single-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 78. Latin America Single-target MET TKIs Market Size, by End User, 2017-2032 (USD Million)
TABLE 79. Europe Single-target MET TKIs Market Size, by Region, 2017-2032 (USD Million)
TABLE 80. Europe Single-target MET TKIs Market Size, by Product, 2017-2032 (USD Million)
TABLE 81. Europe Single-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 82. Europe Single-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 83. Europe Single-target MET TKIs Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 84. Europe Single-target MET TKIs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 85. Europe Single-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 86. Europe Single-target MET TKIs Market Size, by End User, 2017-2032 (USD Million)
TABLE 87. Middle East Single-target MET TKIs Market Size, by Region, 2017-2032 (USD Million)
TABLE 88. Middle East Single-target MET TKIs Market Size, by Product, 2017-2032 (USD Million)
TABLE 89. Middle East Single-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 90. Middle East Single-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 91. Middle East Single-target MET TKIs Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 92. Middle East Single-target MET TKIs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 93. Middle East Single-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 94. Middle East Single-target MET TKIs Market Size, by End User, 2017-2032 (USD Million)
TABLE 95. Africa Single-target MET TKIs Market Size, by Region, 2017-2032 (USD Million)
TABLE 96. Africa Single-target MET TKIs Market Size, by Product, 2017-2032 (USD Million)
TABLE 97. Africa Single-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 98. Africa Single-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 99. Africa Single-target MET TKIs Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 100. Africa Single-target MET TKIs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 101. Africa Single-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 102. Africa Single-target MET TKIs Market Size, by End User, 2017-2032 (USD Million)
TABLE 103. Global Single-target MET TKIs Market Size, by Group, 2017-2032 (USD Million)
TABLE 104. ASEAN Single-target MET TKIs Market Size, by Group, 2017-2032 (USD Million)
TABLE 105. ASEAN Single-target MET TKIs Market Size, by Product, 2017-2032 (USD Million)
TABLE 106. ASEAN Single-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 107. ASEAN Single-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 108. ASEAN Single-target MET TKIs Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 109. ASEAN Single-target MET TKIs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 110. ASEAN Single-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 111. ASEAN Single-target MET TKIs Market Size, by End User, 2017-2032 (USD Million)
TABLE 112. GCC Single-target MET TKIs Market Size, by Group, 2017-2032 (USD Million)
TABLE 113. GCC Single-target MET TKIs Market Size, by Product, 2017-2032 (USD Million)
TABLE 114. GCC Single-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 115. GCC Single-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 116. GCC Single-target MET TKIs Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 117. GCC Single-target MET TKIs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 118. GCC Single-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 119. GCC Single-target MET TKIs Market Size, by End User, 2017-2032 (USD Million)
TABLE 120. European Union Single-target MET TKIs Market Size, by Group, 2017-2032 (USD Million)
TABLE 121. European Union Single-target MET TKIs Market Size, by Product, 2017-2032 (USD Million)
TABLE 122. European Union Single-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 123. European Union Single-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 124. European Union Single-target MET TKIs Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 125. European Union Single-target MET TKIs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 126. European Union Single-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 127. European Union Single-target MET TKIs Market Size, by End User, 2017-2032 (USD Million)
TABLE 128. BRICS Single-target MET TKIs Market Size, by Group, 2017-2032 (USD Million)
TABLE 129. BRICS Single-target MET TKIs Market Size, by Product, 2017-2032 (USD Million)
TABLE 130. BRICS Single-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 131. BRICS Single-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 132. BRICS Single-target MET TKIs Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 133. BRICS Single-target MET TKIs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 134. BRICS Single-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 135. BRICS Single-target MET TKIs Market Size, by End User, 2017-2032 (USD Million)
TABLE 136. G7 Single-target MET TKIs Market Size, by Group, 2017-2032 (USD Million)
TABLE 137. G7 Single-target MET TKIs Market Size, by Product, 2017-2032 (USD Million)
TABLE 138. G7 Single-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 139. G7 Single-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 140. G7 Single-target MET TKIs Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 141. G7 Single-target MET TKIs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 142. G7 Single-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 143. G7 Single-target MET TKIs Market Size, by End User, 2017-2032 (USD Million)
TABLE 144. NATO Single-target MET TKIs Market Size, by Group, 2017-2032 (USD Million)
TABLE 145. NATO Single-target MET TKIs Market Size, by Product, 2017-2032 (USD Million)
TABLE 146. NATO Single-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 147. NATO Single-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 148. NATO Single-target MET TKIs Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 149. NATO Single-target MET TKIs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 150. NATO Single-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 151. NATO Single-target MET TKIs Market Size, by End User, 2017-2032 (USD Million)
TABLE 152. Global Single-target MET TKIs Market Size, by Country, 2017-2032 (USD Million)
TABLE 153. United States Single-target MET TKIs Market Size, 2017-2032 (USD Million)
TABLE 154. United States Single-target MET TKIs Market Size, by Product, 2017-2032 (USD Million)
TABLE 155. United States Single-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 156. United States Single-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 157. United States Single-target MET TKIs Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 158. United States Single-target MET TKIs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 159. United States Single-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 160. United States Single-target MET TKIs Market Size, by End User, 2017-2032 (USD Million)
TABLE 161. Canada Single-target MET TKIs Market Size, 2017-2032 (USD Million)
TABLE 162. Canada Single-target MET TKIs Market Size, by Product, 2017-2032 (USD Million)
TABLE 163. Canada Single-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 164. Canada Single-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 165. Canada Single-target MET TKIs Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 166. Canada Single-target MET TKIs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 167. Canada Single-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 168. Canada Single-target MET TKIs Market Size, by End User, 2017-2032 (USD Million)
TABLE 169. Mexico Single-target MET TKIs Market Size, 2017-2032 (USD Million)
TABLE 170. Mexico Single-target MET TKIs Market Size, by Product, 2017-2032 (USD Million)
TABLE 171. Mexico Single-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 172. Mexico Single-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 173. Mexico Single-target MET TKIs Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 174. Mexico Single-target MET TKIs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 175. Mexico Single-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 176. Mexico Single-target MET TKIs Market Size, by End User, 2017-2032 (USD Million)
TABLE 177. Brazil Single-target MET TKIs Market Size, 2017-2032 (USD Million)
TABLE 178. Brazil Single-target MET TKIs Market Size, by Product, 2017-2032 (USD Million)
TABLE 179. Brazil Single-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 180. Brazil Single-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 181. Brazil Single-target MET TKIs Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 182. Brazil Single-target MET TKIs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 183. Brazil Single-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 184. Brazil Single-target MET TKIs Market Size, by End User, 2017-2032 (USD Million)
TABLE 185. United Kingdom Single-target MET TKIs Market Size, 2017-2032 (USD Million)
TABLE 186. United Kingdom Single-target MET TKIs Market Size, by Product, 2017-2032 (USD Million)
TABLE 187. United Kingdom Single-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 188. United Kingdom Single-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 189. United Kingdom Single-target MET TKIs Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 190. United Kingdom Single-target MET TKIs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 191. United Kingdom Single-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 192. United Kingdom Single-target MET TKIs Market Size, by End User, 2017-2032 (USD Million)
TABLE 193. Germany Single-target MET TKIs Market Size, 2017-2032 (USD Million)
TABLE 194. Germany Single-target MET TKIs Market Size, by Product, 2017-2032 (USD Million)
TABLE 195. Germany Single-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 196. Germany Single-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 197. Germany Single-target MET TKIs Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 198. Germany Single-target MET TKIs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 199. Germany Single-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 200. Germany Single-target MET TKIs Market Size, by End User, 2017-2032 (USD Million)
TABLE 201. France Single-target MET TKIs Market Size, 2017-2032 (USD Million)
TABLE 202. France Single-target MET TKIs Market Size, by Product, 2017-2032 (USD Million)
TABLE 203. France Single-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 204. France Single-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 205. France Single-target MET TKIs Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 206. France Single-target MET TKIs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 207. France Single-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 208. France Single-target MET TKIs Market Size, by End User, 2017-2032 (USD Million)
TABLE 209. Russia Single-target MET TKIs Market Size, 2017-2032 (USD Million)
TABLE 210. Russia Single-target MET TKIs Market Size, by Product, 2017-2032 (USD Million)
TABLE 211. Russia Single-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 212. Russia Single-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 213. Russia Single-target MET TKIs Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 214. Russia Single-target MET TKIs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 215. Russia Single-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 216. Russia Single-target MET TKIs Market Size, by End User, 2017-2032 (USD Million)
TABLE 217. Italy Single-target MET TKIs Market Size, 2017-2032 (USD Million)
TABLE 218. Italy Single-target MET TKIs Market Size, by Product, 2017-2032 (USD Million)
TABLE 219. Italy Single-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 220. Italy Single-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 221. Italy Single-target MET TKIs Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 222. Italy Single-target MET TKIs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 223. Italy Single-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 224. Italy Single-target MET TKIs Market Size, by End User, 2017-2032 (USD Million)
TABLE 225. Spain Single-target MET TKIs Market Size, 2017-2032 (USD Million)
TABLE 226. Spain Single-target MET TKIs Market Size, by Product, 2017-2032 (USD Million)
TABLE 227. Spain Single-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 228. Spain Single-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 229. Spain Single-target MET TKIs Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 230. Spain Single-target MET TKIs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 231. Spain Single-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 232. Spain Single-target MET TKIs Market Size, by End User, 2017-2032 (USD Million)
TABLE 233. China Single-target MET TKIs Market Size, 2017-2032 (USD Million)
TABLE 234. China Single-target MET TKIs Market Size, by Product, 2017-2032 (USD Million)
TABLE 235. China Single-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 236. China Single-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 237. China Single-target MET TKIs Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 238. China Single-target MET TKIs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 239. China Single-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 240. China Single-target MET TKIs Market Size, by End User, 2017-2032 (USD Million)
TABLE 241. India Single-target MET TKIs Market Size, 2017-2032 (USD Million)
TABLE 242. India Single-target MET TKIs Market Size, by Product, 2017-2032 (USD Million)
TABLE 243. India Single-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 244. India Single-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 245. India Single-target MET TKIs Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 246. India Single-target MET TKIs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 247. India Single-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 248. India Single-target MET TKIs Market Size, by End User, 2017-2032 (USD Million)
TABLE 249. Japan Single-target MET TKIs Market Size, 2017-2032 (USD Million)
TABLE 250. Japan Single-target MET TKIs Market Size, by Product, 2017-2032 (USD Million)
TABLE 251. Japan Single-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 252. Japan Single-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 253. Japan Single-target MET TKIs Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 254. Japan Single-target MET TKIs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 255. Japan Single-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 256. Japan Single-target MET TKIs Market Size, by End User, 2017-2032 (USD Million)
TABLE 257. Australia Single-target MET TKIs Market Size, 2017-2032 (USD Million)
TABLE 258. Australia Single-target MET TKIs Market Size, by Product, 2017-2032 (USD Million)
TABLE 259. Australia Single-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 260. Australia Single-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 261. Australia Single-target MET TKIs Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 262. Australia Single-target MET TKIs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 263. Australia Single-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 264. Australia Single-target MET TKIs Market Size, by End User, 2017-2032 (USD Million)
TABLE 265. South Korea Single-target MET TKIs Market Size, 2017-2032 (USD Million)
TABLE 266. South Korea Single-target MET TKIs Market Size, by Product, 2017-2032 (USD Million)
TABLE 267. South Korea Single-target MET TKIs Market Size, by Indication, 2017-2032 (USD Million)
TABLE 268. South Korea Single-target MET TKIs Market Size, by Non Small Cell Lung Cancer, 2017-2032 (USD Million)
TABLE 269. South Korea Single-target MET TKIs Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 270. South Korea Single-target MET TKIs Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 271. South Korea Single-target MET TKIs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 272. South Korea Single-target MET TKIs Market Size, by End User, 2017-2032 (USD Million)
TABLE 273. Global Single-target MET TKIs Market Share, by Key Player, 2025
TABLE 274. Global Single-target MET TKIs Market, Key Experts

Companies Mentioned

  • AbbVie Inc.
  • Apollomics Inc.
  • AstraZeneca PLC
  • Avistone Pharmaceuticals Biotechnology Company
  • BeiGene, Ltd.
  • Blueprint Medicines Corporation
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • Exelixis, Inc.
  • Haihe Biopharma Co., Ltd.
  • Hanmi Pharmaceutical Co., Ltd.
  • HUTCHMED (China) Limited
  • Incyte Corporation
  • Merck KGaA
  • Mirati Therapeutics, Inc.
  • Novartis AG
  • Nuvation Bio Inc.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Repare Therapeutics, Inc.
  • Samsung Bioepis Co., Ltd.
  • Sanofi S.A.
  • Symphogen A/S
  • Takeda Pharmaceutical Company Limited
  • Turning Point Therapeutics, Inc.

Related Topics

Related Reports

Multi-target MET TKIs Market - Global Forecast 2026-2032 - Product Image

Multi-target MET TKIs Market - Global Forecast 2026-2032

  • Report
  • 180 Pages
  • Global
From
MET TKIs Market - Global Forecast 2026-2032 - Product Image

MET TKIs Market - Global Forecast 2026-2032

  • Report
  • 182 Pages
  • Global
From
Gastrointestinal Stromal Tumor (GIST) - Market Insight, Epidemiology, and Market Forecast - 2036 - Product Image

Gastrointestinal Stromal Tumor (GIST) - Market Insight, Epidemiology, and Market Forecast - 2036

  • Report
  • 200 Pages
  • Global
From
Hepatocellular Carcinoma Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology - Product Image

Hepatocellular Carcinoma Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology

  • Report
  • 98 Pages
  • Global
From
Osimertinib Drugs Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Osimertinib Drugs Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.